Cashman Christopher M 4
4 · SANUWAVE Health, Inc. · Filed Nov 13, 2012
Insider Transaction Report
Form 4
Cashman Christopher M
President and CEO
Transactions
- Award
Options
2012-11-06+600,000→ 600,000 totalExercise: $0.21From: 2012-11-06Exp: 2022-11-06→ Common Stock, $0.001 par value (600,000 underlying) - Award
Options
2012-11-06+400,000→ 400,000 totalExercise: $0.21Exp: 2022-11-06→ Common Stock, $0.001 par value (400,000 underlying) - Award
Options
2012-11-06+12,500→ 12,500 totalExercise: $0.21From: 2012-11-06Exp: 2022-11-06→ Common Stock, $0.001 par value (12,500 underlying) - Award
Options
2012-11-06+37,500→ 37,500 totalExercise: $0.21Exp: 2022-11-06→ Common Stock, $0.001 par value (37,500 underlying)
Holdings
- 429,257
Common Stock, $.001 par value
Footnotes (2)
- [F1]The 400,000 options shall vest and become exercisable in increments of 100,000 upon each of the following four events (the "Events"): (i) the first (1st) enrollee in the Company's clinical trial plan, (ii) the twentieth (20th) enrollee, (iii) the fiftieth (50th) enrollee, and (iv) receipt of an FDA approval letter of the dermaPACE device allowance for commercial use; provided, that if the FDA approval letter at subpart (iv) is received prior to the achievement of the enrollment thresholds at subparts (i), (ii), and/or (iii), all options granted under this section but not previously vested shall become vested and immediately exercisable upon receipt of such letter. Any of the Events which have not occurred as of December 31, 2016 shall be considered to have occurred as of December 31, 2016, and all options granted under this section but not previously vested shall become vested and immediately exercisable on such date.
- [F2]The 37,500 options shall vest and be exercisable based on the following schedule subject to the conditions of the advisory service agreement: (i) 12,500 on February 6, 2013; (ii) 12,500 on May 6, 2013; and, (iii) 12,500 on August 6, 2013.